ArticleNature communications2025
Mapping risks of health conditions in people with atopic eczema in English primary care and hospital data.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Atopic eczema may be associated with multiple health conditions. Here, we systematically explore risks across the full health spectrum based on the International Classification of Diseases, assessing associations between eczema and 2058 ICD-10 codes, 1593 phecodes, and 201 Global Burden of Disease codes. In English primary care electronic health records (1997 - 2023) we identify cohorts of people with eczema (up to 3 million) and matched (by age, sex, general practice) comparators without eczema (up to 14 million). In up to 25 years of follow-up, we capture outcomes recorded during hospital admissions. People with eczema show higher rates of several outcomes across multiple organ systems. Among those followed up from eczema diagnosis in childhood, atopic/allergic conditions and infections account for most excess diagnoses. Consistent across cohorts and analyses, large relative risk increases are seen for inflammatory bowel conditions (e.g., K50 Crohn disease, crude hazard ratio 1.70 [1.63-1.77]) and eye diseases (e.g., H16 Keratitis, crude hazard ratio 1.71 [1.57-1.86]). We provide a dashboard to explore and browse the full range of results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.